REBINYN: payments to doctors
Payments that named REBINYN as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $636K
- Providers
- 510
- Transactions
- 1,127
- Average per transaction
- $565
The per-transaction average — $565 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 510 providers the average total is $1,248, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novo Nordisk | $524,493 | 82.4% |
| Novo Nordisk AS | $107,645 | 16.9% |
| Novo Nordisk Health Care AG | $4,165 | 0.7% |